In Brief: Angeion
This article was originally published in The Gray Sheet
Executive Summary
Angeion: Files premarket approval application with FDA for its Sentinel 2000, 2010, 2011 and 2012 series implantable cardioverter defibrillator systems. The electronic PMA submission comes "just 15 months" after initiating U.S. clinical studies of the devices, the firm says ("The Gray Sheet" April 7, In Brief)...